Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)

NCT03062579 is registered in ClinicalTrials.gov with Fu-Dong Shi as lead sponsor.

NCT NCT03062579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03062579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)
Lead sponsor
Fu-Dong Shi
Phase
Phase 1/2
Overall status
Completed
Start date
February 1, 2017
Completion date
May 15, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

devic's disease, neuromyelitis optica, neuromyelitis optica spectrum disorders